Flibanserin is the first FDA-approved drug identified for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. The diagnosis cannot be attributed to relationship issues, psychiatric or medical conditions, or effects of medication or drug use to qualify as an indication for flibanserin therapy. This CME/CE activity will highlight the indications, contraindications, and mechanism of action of flibanserin. In addition, administration, monitoring, and toxicity will be addressed. This activity will support the healthcare team outcomes and proper management of patients with HSDD taking flibanserin.

**Objectives:**
-  Determine the indications and contraindications for the use of flibanserin.
- Understand the mechanism of action of flibanserin.
- Recognize adverse effects of flibanserin use and suggested monitoring strategies.
- Review the medication interactions that can occur with flibanserin.